The St. Louis, MO-based test has 94% sensitivity for colorectal cancer detection. Colosense said it aims to transform gastrointestinal diagnostics, leveraging RNA technology for higher accuracy and ease of use.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,